Why the study?
General anticoagulant evaluation requires expensive equipment, reagents, and space, limiting the ability of all laboratories to perform anticoagulant-related research.
A novel, low-cost in vitro thrombus-growth model can effectively evaluate anticoagulant activity by measuring clot weight, providing an accessible primary screening tool.
Answers are grounded in this paper and cite their sources.
May simplify anticoagulant testing in resource-limited labs; leaves open correlation with clinical outcomes or standard assays.
The general anticoagulant evaluation requires high expense equipment, reagents, and space. Therefore, not all laboratories can perform research related to anticoagulant. In this study, we propose a novel simple method "in vitro thrombus-growth model" that can evaluate anticoagulant ability by measuring weight. The in vitro thrombus-growth model is prepared by creating a "growth-clot" with citrate plasma, calcium chloride, and thrombin, and then pouring new citrate plasma onto it. The prepared growth-clots were increased in volume in citrated human plasma, including surpluses calcium chloride, which was released slowly, leading to clot coagulation around the plasma. As a result of evaluating the anticoagulant ability of direct thrombin inhibitor using this in vitro thrombus-growth model, it was confirmed that clot growth was suppressed in a concentration-dependent manner. Therefore, this thrombus-growth model is useful as a primary anticoagulant test that can to discover compounds with anticoagulant activity perform in any laboratory.
No takes yet. Share an insight, caveat, or question.
Sawaguchi et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: